Daniela Diverio
YOU?
Author Swipe
View article: Rapid and accurate identification of acute promyelocytic leukemia with a novel multiparametric flow cytometric scoring system
Rapid and accurate identification of acute promyelocytic leukemia with a novel multiparametric flow cytometric scoring system Open
Not available.
View article: Different prognosis according to treatment in patients with acute promyelocytic leukemia: How the outcome changed over time
Different prognosis according to treatment in patients with acute promyelocytic leukemia: How the outcome changed over time Open
A comprehensive analysis of 220 patients diagnosed with APL between 1993 and 2022 is here reported. Overall, 214 patients (97.2%) received induction therapy. Complete response (CR) was achieved in 97.4%, 100%, 100%, and 27% of patients tre…
View article: Real-Life Management of FLT3-Mutated AML: Single-Centre Experience over 24 Years
Real-Life Management of FLT3-Mutated AML: Single-Centre Experience over 24 Years Open
We analyzed 140 patients with a median age of 51 years; 21% had WBC ≥ 100 × 109/L, and 52% had an NPM1 co-mutation. Until 2018, 101 patients received chemotherapy; thereafter, 39 received 3+7+midostaurin. The overall CR rate was 64%, highe…
View article: Early death risk score in acute promyelocytic leukemia: A retrospective analysis from a monocentric cohort
Early death risk score in acute promyelocytic leukemia: A retrospective analysis from a monocentric cohort Open
The data that support the findings of this study are available from the corresponding author upon reasonable request.
View article: Outcome of relapsed/refractory acute promyelocytic leukaemia in children, adolescents and young adult patients — a 25‐year Italian experience
Outcome of relapsed/refractory acute promyelocytic leukaemia in children, adolescents and young adult patients — a 25‐year Italian experience Open
Acute promyelocytic leukaemia (APL) is a rare subtype ofchildhood acute myeloid leukaemia (AML), accounting for5–12% of all AML cases. Treatment with all-trans-retinoicacid (ATRA) and anthracyclines yields complete remission(CR) rates >…
View article: Successes in the Evolution of Front-Line Therapy in Pediatric Acute Promyelocytic Leukemia
Successes in the Evolution of Front-Line Therapy in Pediatric Acute Promyelocytic Leukemia Open
The success in APL treatment is due on the one side to the depth of our understanding of the driver PML-RARA mutation and on the other side to the collaborative efforts to quickly introduce and maximize the benefit of innovative therapeuti…
View article: NPM1 MUTATED, BCR-ABL1 POSITIVE MYELOID NEOPLASMS: REVIEW OF LITERATURE
NPM1 MUTATED, BCR-ABL1 POSITIVE MYELOID NEOPLASMS: REVIEW OF LITERATURE Open
Break point cluster region - Abelson (BCR-ABL1) chimeric protein and mutated Nucleophosmin (NPM1) are often present in hematological cancers, but they rarely coexist in the same disease. Both anomalies are considered founder mutations caus…
View article: Molecular Minimal Residual Disease Monitoring In Npm1-Mutated Acute Myeloid Leukemia: A Single Institution Experience
Molecular Minimal Residual Disease Monitoring In Npm1-Mutated Acute Myeloid Leukemia: A Single Institution Experience Open
Introduction: The NPM1mut identification by RQ-PCR at diagnosis is important for AML risk stratification and represents a reliable marker to track minimal residual disease (MRD) and to early detect relapse. We retrospectively analyzed clin…
View article: PS1172 DDPCR AT THE TIME OF TKI DISCONTINUATION IN CHRONIC PHASE CHRONIC MYELOID PATIENTS IS PREDICTIVE OF TREATMENT‐FREE REMISSION OUTCOME
PS1172 DDPCR AT THE TIME OF TKI DISCONTINUATION IN CHRONIC PHASE CHRONIC MYELOID PATIENTS IS PREDICTIVE OF TREATMENT‐FREE REMISSION OUTCOME Open
Background: Only few prognostic factors ‐ the median duration of treatment or of deep molecular response (DMR) ‐ have so far been associated to a positive outcome after TKI discontinuation in chronic myeloid leukemia (CML) patients. Thus, …
View article: Atypical Chronic Myeloid Leukemia in a Patient with Aplastic Anemia
Atypical Chronic Myeloid Leukemia in a Patient with Aplastic Anemia Open
Atypical Chronic Myeloid Leukemia in a Patient with Aplastic Anemia
View article: Incidence of Clinically Significant (≤10 g/dL) Late Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib
Incidence of Clinically Significant (≤10 g/dL) Late Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib Open
Background: In elderly patients with chronic myeloid leukemia (CML) responsive to imatinib, the incidence of clinically significant (CS) late chronic anemia is still unknown. Materials and Methods: To highlight this issue, we revised retro…
View article: Arsenic trioxide and all‐trans retinoic acid treatment for childhood acute promyelocytic leukaemia
Arsenic trioxide and all‐trans retinoic acid treatment for childhood acute promyelocytic leukaemia Open
Acute promyelocytic leukaemia (APL) has evolved from being frequently fatal to a highly curable leukaemia through the combination of all-trans retinoic acid (ATRA) and anthracycline-based chemotherapy, with remission and event-free surviva…
View article: Risk-adapted treatment of acute promyelocytic leukemia: results from the International Consortium for Childhood APL
Risk-adapted treatment of acute promyelocytic leukemia: results from the International Consortium for Childhood APL Open
Key Points Risk-adapted therapy allowed achieving remarkable cure rates in an international trial on childhood APL. Reduction of the anthracycline cumulative dose coupled with ATRA extended use does not compromise the outcome of children w…
View article: Prognostic factors associated with a stable MR4.5 achievement in chronic myeloid leukemia patients treated with imatinib
Prognostic factors associated with a stable MR4.5 achievement in chronic myeloid leukemia patients treated with imatinib Open
Deep molecular response in chronic myeloid leukemia (CML) patients treated with imatinib is a prerequisite for possible discontinuation. We identify clinico-biologic features linked with the probability of reaching MR4.5 (BCR-ABL/ABL ≤ 0.0…
View article: Timing and deepness of response to tyrosine kinase inhibitors as a measure of potential treatment discontinuation in chronic myeloid leukemia patients managed in the real‐life
Timing and deepness of response to tyrosine kinase inhibitors as a measure of potential treatment discontinuation in chronic myeloid leukemia patients managed in the real‐life Open
Discontinuation of treatment and maintenance of response (treatment-free remission or TFR) has become a new endpoint in the management of chronic myeloid leukemia patients in chronic phase (CP-CML) after achievement of a stable and deep mo…
View article: Body mass index does not impact on molecular response rate of chronic myeloid leukaemia patients treated frontline with second generation tyrosine kinase inhibitors
Body mass index does not impact on molecular response rate of chronic myeloid leukaemia patients treated frontline with second generation tyrosine kinase inhibitors Open
...
View article: Long‐term impact of molecular response fluctuations in chronic myeloid leukaemia patients treated with imatinib
Long‐term impact of molecular response fluctuations in chronic myeloid leukaemia patients treated with imatinib Open
The majority of chronic phase chronic myeloid leukaemia (CP-CML) patients achieve a complete cytogenetic response (CCyR) with tyrosine kinase inhibitors (TKIs) (Soverini et al, 2016). Monitoring of minimal residual disease with quantitativ…
View article: Early response does not predict outcome in children and adolescents with chronic myeloid leukaemia treated with high‐dose imatinib
Early response does not predict outcome in children and adolescents with chronic myeloid leukaemia treated with high‐dose imatinib Open
We investigated the predictive value of the 3-month BCR-ABL1 transcript levels in terms of responses and outcome of 44 children and adolescents (<18 years at diagnosis) with chronic myeloid leukemia (CML) treated with high-dose imatinib (I…
View article: Can chronic myeloid leukaemia in children and adolescents be successfully treated without haematopoietic stem cell transplant? A single centre experience
Can chronic myeloid leukaemia in children and adolescents be successfully treated without haematopoietic stem cell transplant? A single centre experience Open
Summary We analysed the long‐term outcome of 35 children and adolescents (<20 years at diagnosis) with chronic myeloid leukaemia ( CML ) in chronic phase: 20 patients had received interferon‐alpha and/or tyrosine kinase inhibitors ( TKI s)…